ConvaTec Group PLC (LON:CTEC) Receives GBX 319 Consensus PT from Brokerages

ConvaTec Group PLC (LON:CTEC) has earned an average recommendation of “Buy” from the eight brokerages that are covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is GBX 319.

A number of analysts have recently weighed in on the stock. Stifel Nicolaus restated a “buy” rating and issued a GBX 315 price target on shares of ConvaTec Group in a report on Wednesday. Berenberg Bank boosted their price objective on shares of ConvaTec Group from GBX 330 to GBX 340 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Citigroup reissued an “outperform” rating and set a GBX 315 target price on shares of ConvaTec Group in a research report on Thursday, March 5th.

ConvaTec Group Price Performance

CTEC opened at GBX 237.60 on Thursday. The firm has a market capitalization of £4.63 billion, a PE ratio of 27.63, a price-to-earnings-growth ratio of 0.93 and a beta of 0.76. The company has a debt-to-equity ratio of 106.19, a current ratio of 1.53 and a quick ratio of 0.96. The business’s 50-day moving average is GBX 235.65 and its two-hundred day moving average is GBX 236.67. ConvaTec Group has a 1 year low of GBX 209.40 and a 1 year high of GBX 311.20.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.